AACR logo

More articles from Research Articles: Therapeutics, Targets, and Development

Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy
Yunqing Li, Fadila Guessous, Charles DiPierro, Ying Zhang, Tucker Mudrick, Lauren Fuller, Elizabeth Johnson, Lukasz Marcinkiewicz, Matthew Engelhardt, Benjamin Kefas, David Schiff, Jin Kim, Roger Abounader

Molecular Cancer Therapeutics Feb 2009, 8 (2) 376-385; DOI: 10.1158/1535-7163.MCT-08-0627
Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells
Gary L. Gallia, Betty M. Tyler, Christine L. Hann, I-Mei Siu, Vincent L. Giranda, Angelo L. Vescovi, Henry Brem, Gregory J. Riggins

Molecular Cancer Therapeutics Feb 2009, 8 (2) 386-393; DOI: 10.1158/1535-7163.MCT-08-0680
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma
Vanessa Milano, Yuji Piao, Tiffany LaFortune, John de Groot

Molecular Cancer Therapeutics Feb 2009, 8 (2) 394-406; DOI: 10.1158/1535-7163.MCT-08-0669
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines
Michelle J. Clarke, Evan A. Mulligan, Patrick T. Grogan, Ann C. Mladek, Brett L. Carlson, Mark A. Schroeder, Nicola J. Curtin, Zhenkun Lou, Paul A. Decker, Wenting Wu, E. Ruth Plummer, Jann N. Sarkaria

Molecular Cancer Therapeutics Feb 2009, 8 (2) 407-414; DOI: 10.1158/1535-7163.MCT-08-0854
Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma
Wing Lam, Scott Bussom, Yung-Chi Cheng

Molecular Cancer Therapeutics Feb 2009, 8 (2) 415-423; DOI: 10.1158/1535-7163.MCT-08-0692
Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells
Cristina Morales, Maria J. García, Maria Ribas, Rosa Miró, Mar Muñoz, Carlos Caldas, Miguel A. Peinado

Molecular Cancer Therapeutics Feb 2009, 8 (2) 424-432; DOI: 10.1158/1535-7163.MCT-08-0759
MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib
Roland Houben, Heike Voigt, Christiane Noelke, Valeska Hofmeister, Juergen C. Becker, David Schrama

Molecular Cancer Therapeutics Feb 2009, 8 (2) 433-440; DOI: 10.1158/1535-7163.MCT-08-1051
Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1)
Wei Guo, Shuhong Wu, Li Wang, Rui-yu Wang, Xiaoli Wei, Jinsong Liu, Bingliang Fang

Molecular Cancer Therapeutics Feb 2009, 8 (2) 441-448; DOI: 10.1158/1535-7163.MCT-08-0839
Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors
Claudia Forni, Mario Minuzzo, Emanuela Virdis, Elena Tamborini, Matteo Simone, Michele Tavecchio, Eugenio Erba, Federica Grosso, Alessandro Gronchi, Pierre Aman, Paolo Casali, Maurizio D'Incalci, Silvana Pilotti, Roberto Mantovani

Molecular Cancer Therapeutics Feb 2009, 8 (2) 449-457; DOI: 10.1158/1535-7163.MCT-08-0848
Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors
Xueming Xiao, Li Ning, Herbert Chen

Molecular Cancer Therapeutics Feb 2009, 8 (2) 350-356; DOI: 10.1158/1535-7163.MCT-08-0585

Main menu

User menu

Search

More articles from Research Articles: Therapeutics, Targets, and Development

Pages

Articles

Info for

About MCT